Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors.

Int J Mol Sci

Brain Tumor and Immune Cell Engineering Laboratory, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.

Published: October 2020

Malignant brain tumors remain incurable diseases. Although much effort has been devoted to improving patient outcome, multiple factors such as the high tumor heterogeneity, the strong tumor-induced immunosuppressive microenvironment, and the low mutational burden make the treatment of these tumors especially challenging. Thus, novel therapeutic strategies are urgent. Oncolytic viruses (OVs) are biotherapeutics that have been selected or engineered to infect and selectively kill cancer cells. Increasingly, preclinical and clinical studies demonstrate the ability of OVs to recruit T cells and induce durable immune responses against both virus and tumor, transforming a "cold" tumor microenvironment into a "hot" environment. Besides promising clinical results as a monotherapy, OVs can be powerfully combined with other cancer therapies, helping to overcome critical barriers through the creation of synergistic effects in the fight against brain cancer. Although many questions remain to be answered to fully exploit the therapeutic potential of OVs, oncolytic virotherapy will clearly be part of future treatments for patients with malignant brain tumors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589928PMC
http://dx.doi.org/10.3390/ijms21207449DOI Listing

Publication Analysis

Top Keywords

malignant brain
12
brain tumors
12
oncolytic viruses
8
viruses platform
4
platform treatment
4
treatment malignant
4
brain
4
tumors
4
tumors malignant
4
tumors remain
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!